<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reinfusion of undetected <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells is a possible cause of relapse after autologous bone-marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>In this paper, a system for in-vitro purging of bone marrow is presented which involves the B-cell <z:hpo ids='HP_0002664'>neoplasia</z:hpo>-associated monoclonal antibody anti-Y 29/55 and complement </plain></SENT>
<SENT sid="2" pm="."><plain>Five patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were transplanted with purged marrow, demonstrating the clinical feasibility of the method </plain></SENT>
<SENT sid="3" pm="."><plain>The pretransplant regimen included <z:chebi fb="0" ids="28445">vincristine</z:chebi> 2 mg/m2, adriamycin 60 mg/m2, four doses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 45 mg/kg and total body irradiation with 6 Gy </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> control appears to be better in patients with purged bone marrow as compared to an earlier patient group with unpurged marrow </plain></SENT>
</text></document>